KR101662975B1 - 간암 치료 또는 예방용 조성물 - Google Patents

간암 치료 또는 예방용 조성물 Download PDF

Info

Publication number
KR101662975B1
KR101662975B1 KR1020160017187A KR20160017187A KR101662975B1 KR 101662975 B1 KR101662975 B1 KR 101662975B1 KR 1020160017187 A KR1020160017187 A KR 1020160017187A KR 20160017187 A KR20160017187 A KR 20160017187A KR 101662975 B1 KR101662975 B1 KR 101662975B1
Authority
KR
South Korea
Prior art keywords
hepatocellular carcinoma
cells
pi3k
tert
hcc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020160017187A
Other languages
English (en)
Korean (ko)
Inventor
정구흥
고은경
김윤준
Original Assignee
서울대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교산학협력단 filed Critical 서울대학교산학협력단
Priority to KR1020160017187A priority Critical patent/KR101662975B1/ko
Application granted granted Critical
Publication of KR101662975B1 publication Critical patent/KR101662975B1/ko
Priority to PCT/KR2017/001575 priority patent/WO2017142283A1/ko
Priority to CN201780023517.4A priority patent/CN109069513B/zh
Priority to US15/998,556 priority patent/US10463669B2/en
Priority to JP2018561462A priority patent/JP6871638B2/ja
Assigned to 주식회사 마스터메디텍 reassignment 주식회사 마스터메디텍 권리의 전부이전등록 Assignors: 서울대학교산학협력단
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020160017187A 2016-02-15 2016-02-15 간암 치료 또는 예방용 조성물 Active KR101662975B1 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020160017187A KR101662975B1 (ko) 2016-02-15 2016-02-15 간암 치료 또는 예방용 조성물
PCT/KR2017/001575 WO2017142283A1 (ko) 2016-02-15 2017-02-14 간암 치료 또는 예방용 조성물
CN201780023517.4A CN109069513B (zh) 2016-02-15 2017-02-14 用于治疗或预防肝癌的组合物
US15/998,556 US10463669B2 (en) 2016-02-15 2017-02-14 Composition for treating or preventing liver cancer
JP2018561462A JP6871638B2 (ja) 2016-02-15 2017-02-14 肝癌の治療または予防用組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160017187A KR101662975B1 (ko) 2016-02-15 2016-02-15 간암 치료 또는 예방용 조성물

Publications (1)

Publication Number Publication Date
KR101662975B1 true KR101662975B1 (ko) 2016-10-06

Family

ID=57164552

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160017187A Active KR101662975B1 (ko) 2016-02-15 2016-02-15 간암 치료 또는 예방용 조성물

Country Status (5)

Country Link
US (1) US10463669B2 (https=)
JP (1) JP6871638B2 (https=)
KR (1) KR101662975B1 (https=)
CN (1) CN109069513B (https=)
WO (1) WO2017142283A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017142283A1 (ko) * 2016-02-15 2017-08-24 서울대학교산학협력단 간암 치료 또는 예방용 조성물
KR20220148567A (ko) 2021-04-29 2022-11-07 주식회사 서지넥스 약물전달물질로서의 간세포암 특이적 표적 엑소좀 조성물 및 이의 용도
KR20230112770A (ko) 2022-01-20 2023-07-28 가톨릭대학교 산학협력단 항섬유화 억제용 조성물
KR20250044972A (ko) 2023-09-25 2025-04-01 주식회사 마스터메디텍 이델라리십 함유 경구투여용 고형제제 및 그 제조방법

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019121872A1 (en) * 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
CN110665007A (zh) * 2019-09-19 2020-01-10 邦世（苏州）生物医药科技有限公司 一种治疗癌症用组合药物及其用途
CN114796482A (zh) * 2022-05-31 2022-07-29 江苏省人民医院（南京医科大学第一附属医院） gsk3β抑制剂在制备提高抗肝细胞肝癌疗效的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458410A (zh) * 2009-04-20 2012-05-16 吉联亚·卡利斯托加有限责任公司 治疗实体瘤的方法
EA201270184A1 (ru) * 2009-07-21 2012-08-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Лечение расстройств печени ингибиторами pi3k
WO2013082540A1 (en) * 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
WO2014046617A1 (en) * 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions and methods for treating cancer
KR101418161B1 (ko) * 2012-09-26 2014-07-09 부경대학교 산학협력단 네퍼린을 유효성분으로 포함하는 간암 예방 또는 치료용 약제학적 조성물
CN105491883B (zh) * 2013-06-13 2018-11-02 生物马特里卡公司 细胞稳定化
CN104817559B (zh) * 2014-01-30 2021-05-25 苏州泽璟生物制药股份有限公司 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
WO2016097314A1 (en) * 2014-12-19 2016-06-23 Sandoz Ag Amorphous and crystalline forms of idelalisib and process for forming the same
KR101662975B1 (ko) * 2016-02-15 2016-10-06 서울대학교산학협력단 간암 치료 또는 예방용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Clin. Cancer. Res., 2015.04., Vol.21, No.7., pp 1537-1542 *
Journal of Hematology & Oncology 2013., Vol.6. No.88.
Journal of Hematology & Oncology 2013., Vol.6. No.88. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017142283A1 (ko) * 2016-02-15 2017-08-24 서울대학교산학협력단 간암 치료 또는 예방용 조성물
KR20220148567A (ko) 2021-04-29 2022-11-07 주식회사 서지넥스 약물전달물질로서의 간세포암 특이적 표적 엑소좀 조성물 및 이의 용도
KR20230112770A (ko) 2022-01-20 2023-07-28 가톨릭대학교 산학협력단 항섬유화 억제용 조성물
KR20250044972A (ko) 2023-09-25 2025-04-01 주식회사 마스터메디텍 이델라리십 함유 경구투여용 고형제제 및 그 제조방법

Also Published As

Publication number Publication date
US20190160073A1 (en) 2019-05-30
WO2017142283A1 (ko) 2017-08-24
JP2019510075A (ja) 2019-04-11
CN109069513B (zh) 2021-12-28
CN109069513A (zh) 2018-12-21
US10463669B2 (en) 2019-11-05
JP6871638B2 (ja) 2021-05-12

Similar Documents

Publication Publication Date Title
KR101662975B1 (ko) 간암 치료 또는 예방용 조성물
Yasukawa et al. CDK1 dependent phosphorylation of hTERT contributes to cancer progression
Mao et al. CBX2 regulates proliferation and apoptosis via the phosphorylation of YAP in hepatocellular carcinoma
Ko et al. Telomere length and reactive oxygen species levels are positively associated with a high risk of mortality and recurrence in hepatocellular carcinoma
Ko et al. SERPINA3 is a key modulator of HNRNP-K transcriptional activity against oxidative stress in HCC
Zhang et al. Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma
Xu et al. LncSHRG promotes hepatocellular carcinoma progression by activating HES6
Liu et al. Neutrophil extracellular traps promote gastric cancer cell metastasis via the NAT10-mediated N4-acetylcytidine modification of SMYD2
Su et al. Targeting p38γ to inhibit human colorectal cancer cell progression
Seo et al. PTEN/AKT signaling pathway related to hTERT downregulation and telomere shortening induced in Toxoplasma GRA16-expressing colorectal cancer cells
Matboli et al. Pantoprazole attenuates tumorigenesis via inhibition of exosomal secretion in a rat model of hepatic precancerous lesion induced by diethylnitrosamine and 2‐acetamidofluorene
Mi et al. ACSS2/AMPK/PCNA pathway-driven proliferation and chemoresistance of esophageal squamous carcinoma cells under nutrient stress
Xu et al. ApoM suppresses kidney renal clear cell carcinoma growth and metastasis via the Hippo-YAP signaling pathway
RU2665952C2 (ru) Синтетическая летальность и лечение рака
Xian et al. SNORD99 promotes endometrial cancer development by inhibiting GSDMD‐mediated pyroptosis through 2'‐O‐methylation modification
Struve et al. Increased replication stress and R-loop accumulation in EGFRvIII-expressing glioblastoma present new therapeutic opportunities
Dong et al. The E3 Ligase NEDD4L prevents colorectal cancer liver metastasis via degradation of PRMT5 to inhibit the AKT/mTOR signaling pathway
Li et al. Inhibition of KDM5B participates in immune microenvironment remodeling in pancreatic cancer by inducing STING expression
Kong et al. RETRACTED: Okadaic acid promotes epithelial‐mesenchymal transition of hepatocellular carcinoma cells by inhibiting protein phosphatase 2A
WO2016008051A1 (en) Contactin-1 (cntn1) for use in methods of diagnosis and treatment of prostate cancer
US8809295B2 (en) Composition containing inhibitors of the expression or activity of SH3RF2 for preventing or treating cancer
US10125358B2 (en) Methods and compounds for increasing threonyl-tRNA synthetase activity
US10087435B2 (en) Methods and compounds for reducing threonyl-tRNA synthetase activity
CN118286467B (zh) 整合应激反应抑制剂isrib在治疗肝癌中的应用
Ma et al. Suppressing SMURF1 to preserve GSTM2: An approach to reducing gastric cancer aggressiveness in vitro and in vivo

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20190902

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000